WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013056248) TREATMENT OF BREAST CANCER WITH COMPANION DIAGNOSTIC
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/056248    International Application No.:    PCT/US2012/060288
Publication Date: 18.04.2013 International Filing Date: 15.10.2012
IPC:
A61K 39/395 (2006.01), A61K 38/10 (2006.01), A61K 38/16 (2006.01), A61K 48/00 (2006.01), A61P 35/00 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street Oakland, CA 94607-5200 (US)
Inventors: WADEHRA, Madhuri; (US).
BRAUN, Jonathan; (US)
Agent: PARENT, Annette; Morgan, Lewis & Bockius LLP One Market, Spear Street Tower San Francisco, CA 94105 (US)
Priority Data:
61/546,982 13.10.2011 US
Title (EN) TREATMENT OF BREAST CANCER WITH COMPANION DIAGNOSTIC
(FR) TRAITEMENT DU CANCER DU SEIN PAR UN DIAGNOSTIC COMPAGNON
Abstract: front page image
(EN)Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the BRCA1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (Her-2/new), which accounts for approximately half of all breast cancer deaths. Provided herein are compositions and methods for treating breast cancer, including the triple negative subtype.
(FR)Selon l'invention, malgré des avancées en thérapie, le cancer du sein reste la maladie la plus commune chez les femmes. Une inquiétude particulière concerne le sous-type triple négatif agressif qui est dépourvu de la mutation BRCA1, d'un récepteur des œstrogènes et du récepteur du facteur de type 2 de croissance épidermique (Her-2/nouveau) qui concerne approximativement la moitié de toutes les morts dues au cancer du sein. La présente invention concerne des compositions et des méthodes pour le traitement du cancer du sein, comprenant le sous-type triple négatif.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)